{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Ma L"],"pubmed_abstract":["Background
Outcomes of patients with unresectable hepatocellular carcinoma (HCC) who achieve clinical complete response (cCR) to PD-1 inhibitor-based combination therapy are unclear. This study aimed to explore whether cCR after combination therapy is an accurate and reliable prognostic indicator and to identify predictors of cCR and pathological complete response that could aid in managing patients with HCC.Methods
Data were analyzed retrospectively for 1,266 patients with initially unresectable HCC who received combination therapy involving PD-1 inhibitors and interventional therapy at 23 medical centers across China between 2019 and 2023. Survival was compared between patients who showed cCR or not after combination therapy, and subgroup analyses differentiated further b"],"journal":["Liver cancer"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12810982"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)."],"pmcid":["PMC12810982"],"pubmed_authors":["Pang QQ","Yan YH","Lai YC","Liu J","Pan LX","Lu SC","Ma L","Nong JL","Liu Z","Li ZC","Guo PP","Yao HB","Wu PS","Su Z","Zhong JH","Wang XY","Li MJ","Chen K","Yang FQ","Dong XF","Zhong TM","Yu YQ","Zeng FJ","Liu SP","Yang DL","Li FX","Li WF","Yang YY","Ye L","Luo M","Wu MS","Liang YR","Chen SC","Peng N","Wang GD","GUIDANCE Investigators","Qin C"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).","description":"Background
Outcomes of patients with unresectable hepatocellular carcinoma (HCC) who achieve clinical complete response (cCR) to PD-1 inhibitor-based combination therapy are unclear. This study aimed to explore whether cCR after combination therapy is an accurate and reliable prognostic indicator and to identify predictors of cCR and pathological complete response that could aid in managing patients with HCC.Methods
Data were analyzed retrospectively for 1,266 patients with initially unresectable HCC who received combination therapy involving PD-1 inhibitors and interventional therapy at 23 medical centers across China between 2019 and 2023. Survival was compared between patients who showed cCR or not after combination therapy, and subgroup analyses differentiated further b","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T15:38:31.842Z","creation":"2026-06-02T03:08:55.87Z"},"accession":"S-EPMC12810982","cross_references":{"pubmed":["41551719"],"doi":["10.1159/000549844"]}}